Compare BSET & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSET | SGMT |
|---|---|---|
| Founded | 1902 | 2006 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 164.6M |
| IPO Year | 1995 | 2021 |
| Metric | BSET | SGMT |
|---|---|---|
| Price | $15.35 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 15.7K | ★ 688.4K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.35% | N/A |
| EPS Growth | ★ 163.06 | 45.49 |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $456,855,000.00 | $2,000,000.00 |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $21.34 | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $13.96 | $1.73 |
| 52 Week High | $19.75 | $11.41 |
| Indicator | BSET | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 40.81 |
| Support Level | $15.70 | $4.92 |
| Resistance Level | $16.62 | $5.29 |
| Average True Range (ATR) | 0.67 | 0.51 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 7.94 | 13.38 |
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.